ESMO Media Releases

Preliminary data from a phase III trial suggest drug is well tolerated and leads to a sustained response in patients who have progressed after ipilimumab therapy

High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target

Vemurafenib + cobimetinib achieves significant progression-free survival and response rates in melanoma. Phase III trial data shows better outcomes with combination therapy than vemurafenib alone.

Experts are divided on the value of lung cancer vaccination after disappointing results from the MAGRIT phase III trial.

Treatments for advanced cancer are often unavailable or available only at substantial out of pocket cost in many Eastern European countries compared to those in Western Europe

Dual targeting with pertuzumab and trastuzumab plus chemotherapy has become the new standard therapy in metastatic HER2 positive breast cancer

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them

New initiative aims to promote exchange of ideas among female oncologists and support women with cancer in Greece

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival

Long-term follow-up from CLEOPATRA study presented at ESMO 2014 demonstrates ‘unprecedented’ benefit

Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy.

Phase III trials presented at the ESMO 2014 Congress report major advances in supportive care for cancer patients.